Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Alpha-1 antitrypsin treatment of new-onset type 1 diabetes: An open-label, phase I clinical trial (RETAIN) to assess safety and pharmacokinetics.

Weir GC, Ehlers MR, Harris KM, Kanaparthi S, Long A, Phippard D, Weiner LJ, Jepson B, McNamara JG, Koulmanda M, Strom TB; ITN RETAIN Study Team.

Pediatr Diabetes. 2018 Aug;19(5):945-954. doi: 10.1111/pedi.12660. Epub 2018 May 7.

PMID:
29473705
2.

Who let the dogs out? The ever-present threat of autoreactive T cells.

Ehlers MR.

Sci Immunol. 2018 Feb 2;3(20). pii: eaar6602. doi: 10.1126/sciimmunol.aar6602. Epub 2018 Feb 2. Review.

PMID:
29429979
3.

Glycan microarray reveal induced IgGs repertoire shift against a dietary carbohydrate in response to rabbit anti-human thymocyte therapy.

Amon R, Ben-Arye SL, Engler L, Yu H, Lim N, Berre LL, Harris KM, Ehlers MR, Gitelman SE, Chen X, Soulillou JP, Padler-Karavani V.

Oncotarget. 2017 Dec 11;8(68):112236-112244. doi: 10.18632/oncotarget.23096. eCollection 2017 Dec 22.

4.

Acute psychophysiological stress impairs human associative learning.

Ehlers MR, Todd RM.

Neurobiol Learn Mem. 2017 Nov;145:84-93. doi: 10.1016/j.nlm.2017.09.003. Epub 2017 Sep 8.

PMID:
28893670
5.

Genesis and Maintenance of Attentional Biases: The Role of the Locus Coeruleus-Noradrenaline System.

Ehlers MR, Todd RM.

Neural Plast. 2017;2017:6817349. doi: 10.1155/2017/6817349. Epub 2017 Jul 20. Review.

6.

Anti-Gal and Anti-Neu5Gc Responses in Nonimmunosuppressed Patients After Treatment With Rabbit Antithymocyte Polyclonal IgGs.

Salama A, Evanno G, Lim N, Rousse J, Le Berre L, Nicot A, Bach JM, Brouard S, Harris KM, Ehlers MR, Gitelman SE, Soulillou JP.

Transplantation. 2017 Oct;101(10):2501-2507. doi: 10.1097/TP.0000000000001686.

PMID:
28198767
7.

Correlation Among Hypoglycemia, Glycemic Variability, and C-Peptide Preservation After Alefacept Therapy in Patients with Type 1 Diabetes Mellitus: Analysis of Data from the Immune Tolerance Network T1DAL Trial.

Pinckney A, Rigby MR, Keyes-Elstein L, Soppe CL, Nepom GT, Ehlers MR.

Clin Ther. 2016 Jun;38(6):1327-1339. doi: 10.1016/j.clinthera.2016.04.032. Epub 2016 May 18.

8.

Two- and Four-Hour Tests Differ in Capture of C-Peptide Responses to a Mixed Meal in Type 1 Diabetes.

Boyle KD, Keyes-Elstein L, Ehlers MR, McNamara J, Rigby MR, Gitelman SE, Weiner LJ, Much KL, Herold KC.

Diabetes Care. 2016 Jun;39(6):e76-8. doi: 10.2337/dc15-2077. Epub 2016 Apr 13. No abstract available.

9.

Strategies for clinical trials in type 1 diabetes.

Ehlers MR.

J Autoimmun. 2016 Jul;71:88-96. doi: 10.1016/j.jaut.2016.03.008. Epub 2016 Apr 5. Review.

10.

Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial.

Gitelman SE, Gottlieb PA, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Harris KM, Kanaparthi S, Phippard D, Ding L, Bluestone JA, Ehlers MR; ITN START Study Team.

Diabetologia. 2016 Jun;59(6):1153-61. doi: 10.1007/s00125-016-3917-4. Epub 2016 Apr 6.

11.

A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice.

Gill RG, Pagni PP, Kupfer T, Wasserfall CH, Deng S, Posgai A, Manenkova Y, Bel Hani A, Straub L, Bernstein P, Atkinson MA, Herold KC, von Herrath M, Staeva T, Ehlers MR, Nepom GT.

Diabetes. 2016 May;65(5):1310-6. doi: 10.2337/db15-0492. Epub 2015 Dec 30.

12.

What BANE can offer GANE: Individual differences in function of hotspot mechanisms.

Todd RM, Ehlers MR, Anderson AK.

Behav Brain Sci. 2016 Jan;39:e226. doi: 10.1017/S0140525X15001971.

PMID:
28347362
13.

Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes.

Tooley JE, Vudattu N, Choi J, Cotsapas C, Devine L, Raddassi K, Ehlers MR, McNamara JG, Harris KM, Kanaparthi S, Phippard D, Herold KC.

Eur J Immunol. 2016 Jan;46(1):230-41. doi: 10.1002/eji.201545708. Epub 2015 Dec 14.

14.

Targeting memory T cells in type 1 diabetes.

Ehlers MR, Rigby MR.

Curr Diab Rep. 2015 Nov;15(11):84. doi: 10.1007/s11892-015-0659-5. Review.

PMID:
26370695
15.

Immune interventions to preserve β cell function in type 1 diabetes.

Ehlers MR.

J Investig Med. 2016 Jan;64(1):7-13. Review.

16.

Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.

Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR.

J Clin Invest. 2015 Aug 3;125(8):3285-96. doi: 10.1172/JCI81722. Epub 2015 Jul 20.

17.

Neurogenetic variations in norepinephrine availability enhance perceptual vividness.

Todd RM, Ehlers MR, Müller DJ, Robertson A, Palombo DJ, Freeman N, Levine B, Anderson AK.

J Neurosci. 2015 Apr 22;35(16):6506-16. doi: 10.1523/JNEUROSCI.4489-14.2015.

18.

The P300 in middle cerebral artery strokes or hemorrhages: Outcome predictions and source localization.

Ehlers MR, López Herrero C, Kastrup A, Hildebrandt H.

Clin Neurophysiol. 2015 Aug;126(8):1532-8. doi: 10.1016/j.clinph.2014.10.151. Epub 2014 Nov 1.

PMID:
25465358
19.

Targeted immune interventions for type 1 diabetes: not as easy as it looks!

Rigby MR, Ehlers MR.

Curr Opin Endocrinol Diabetes Obes. 2014 Aug;21(4):271-8. doi: 10.1097/MED.0000000000000075. Review.

20.

Immune-modulating effects of alpha-1 antitrypsin.

Ehlers MR.

Biol Chem. 2014 Oct;395(10):1187-93. doi: 10.1515/hsz-2014-0161. Review.

21.

Restoring the balance: immunotherapeutic combinations for autoimmune disease.

Smilek DE, Ehlers MR, Nepom GT.

Dis Model Mech. 2014 May;7(5):503-13. doi: 10.1242/dmm.015099. Review.

22.

Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial.

Gitelman SE, Gottlieb PA, Rigby MR, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, Ding L, Bluestone JA, Ehlers MR; START Study Team.

Lancet Diabetes Endocrinol. 2013 Dec;1(4):306-16. doi: 10.1016/S2213-8587(13)70065-2. Epub 2013 Aug 28.

PMID:
24622416
23.

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.

Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR; T1DAL Study Team.

Lancet Diabetes Endocrinol. 2013 Dec;1(4):284-94. doi: 10.1016/S2213-8587(13)70111-6. Epub 2013 Sep 23.

24.
25.

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.

Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA; AbATE Study Team.

Diabetes. 2013 Nov;62(11):3766-74. doi: 10.2337/db13-0345. Epub 2013 Jul 8.

26.

C domain-selective inhibition of angiotensin-converting enzyme.

Ehlers MR, Abrie JA, Sturrock ED.

J Renin Angiotensin Aldosterone Syst. 2013 Jun;14(2):189-92. doi: 10.1177/1470320313489206. No abstract available.

PMID:
23686914
27.

Antifibrotic peptide N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP): opportunities for angiotensin-converting enzyme inhibitor design.

Douglas RG, Ehlers MR, Sturrock ED.

Clin Exp Pharmacol Physiol. 2013 Aug;40(8):535-41. doi: 10.1111/1440-1681.12062. Review.

PMID:
23351021
28.

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.

Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum CJ; Diabetes TrialNet and the Immune Tolerance Network.

Diabetes. 2012 Sep;61(9):2340-8. doi: 10.2337/db12-0049. Epub 2012 Jun 20.

29.

Shedding the load of hypertension: the proteolytic processing of angiotensin-converting enzyme.

Ehlers MR, Gordon K, Schwager SL, Sturrock ED.

S Afr Med J. 2012 Mar 2;102(6):461-4. Review.

PMID:
22668937
30.

Immune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experience.

Ehlers MR, Nepom GT.

Rev Diabet Stud. 2012 Winter;9(4):359-71. doi: 10.1900/RDS.2012.9.359. Epub 2012 Dec 28. Review.

31.

Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes.

Torekov SS, Kipnes MS, Harley RE, Holst JJ, Ehlers MR.

Diabetes Obes Metab. 2011 Jul;13(7):639-43. doi: 10.1111/j.1463-1326.2011.01388.x.

PMID:
21362122
32.

Pacific biomarkers, inc.

Ehlers MR.

Biomark Med. 2008 Jun;2(3):221-7. doi: 10.2217/17520363.2.3.221.

33.

Safety issues associated with the use of angiotensin-converting enzyme inhibitors.

Ehlers MR.

Expert Opin Drug Saf. 2006 Nov;5(6):739-40. No abstract available.

PMID:
17044798
34.

Homologous substitution of ACE C-domain regions with N-domain sequences: effect on processing, shedding, and catalytic properties.

Woodman ZL, Schwager SL, Redelinghuys P, Chubb AJ, van der Merwe EL, Ehlers MR, Sturrock ED.

Biol Chem. 2006 Aug;387(8):1043-51.

PMID:
16895474
35.

The N domain of somatic angiotensin-converting enzyme negatively regulates ectodomain shedding and catalytic activity.

Woodman ZL, Schwager SL, Redelinghuys P, Carmona AK, Ehlers MR, Sturrock ED.

Biochem J. 2005 Aug 1;389(Pt 3):739-44.

36.

Deletion of the cytoplasmic domain increases basal shedding of angiotensin-converting enzyme.

Chubb AJ, Schwager SL, van der Merwe E, Ehlers MR, Sturrock ED.

Biochem Biophys Res Commun. 2004 Feb 20;314(4):971-5.

PMID:
14751227
37.

Ace revisited: a new target for structure-based drug design.

Acharya KR, Sturrock ED, Riordan JF, Ehlers MR.

Nat Rev Drug Discov. 2003 Nov;2(11):891-902. Review. No abstract available.

PMID:
14668810
38.

Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes.

Ehlers MR, Klaff LJ, D'Alessio DA, Brazg R, Kay HD, Harley RE, Mathisen AL, Schneider R.

Horm Metab Res. 2003 Oct;35(10):611-6.

PMID:
14605997
39.

Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium.

Kavianipour M, Ehlers MR, Malmberg K, Ronquist G, Ryden L, Wikström G, Gutniak M.

Peptides. 2003 Apr;24(4):569-78.

PMID:
12860201
40.

Effect of glucagon-like peptide 1 (7-36 amide) on insulin-mediated glucose uptake in patients with type 1 diabetes.

Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Ehlers MR, Egan JM, Elahi D.

Diabetes Care. 2003 Mar;26(3):837-42.

PMID:
12610046
41.

Deglycosylation, processing and crystallization of human testis angiotensin-converting enzyme.

Gordon K, Redelinghuys P, Schwager SL, Ehlers MR, Papageorgiou AC, Natesh R, Acharya KR, Sturrock ED.

Biochem J. 2003 Apr 15;371(Pt 2):437-42.

42.

Defining the boundaries of the testis angiotensin I-converting enzyme ectodomain.

Chubb AJ, Schwager SL, Woodman ZL, Ehlers MR, Sturrock ED.

Biochem Biophys Res Commun. 2002 Oct 11;297(5):1225-30.

PMID:
12372418
43.
44.

Cleavage of disulfide-bridged stalk domains during shedding of angiotensin-converting enzyme occurs at multiple juxtamembrane sites.

Schwager SL, Chubb AJ, Woodman ZL, Yan L, Mentele R, Ehlers MR, Sturrock ED.

Biochemistry. 2001 Dec 25;40(51):15624-30.

PMID:
11747437
45.

Roles of the juxtamembrane and extracellular domains of angiotensin-converting enzyme in ectodomain shedding.

Pang S, Chubb AJ, Schwager SL, Ehlers MR, Sturrock ED, Hooper NM.

Biochem J. 2001 Aug 15;358(Pt 1):185-92.

46.
47.

The mycosins of Mycobacterium tuberculosis H37Rv: a family of subtilisin-like serine proteases.

Brown GD, Dave JA, Gey van Pittius NC, Stevens L, Ehlers MR, Beyers AD.

Gene. 2000 Aug 22;254(1-2):147-55.

PMID:
10974545
48.

Shedding of somatic angiotensin-converting enzyme (ACE) is inefficient compared with testis ACE despite cleavage at identical stalk sites.

Woodman ZL, Oppong SY, Cook S, Hooper NM, Schwager SL, Brandt WF, Ehlers MR, Sturrock ED.

Biochem J. 2000 May 1;347 Pt 3:711-8.

49.

CR3: a general purpose adhesion-recognition receptor essential for innate immunity.

Ehlers MR.

Microbes Infect. 2000 Mar;2(3):289-94. Review.

PMID:
10758405
50.

Modulation of juxtamembrane cleavage ("shedding") of angiotensin-converting enzyme by stalk glycosylation: evidence for an alternative shedding protease.

Schwager SL, Chubb AJ, Scholle RR, Brandt WF, Mentele R, Riordan JF, Sturrock ED, Ehlers MR.

Biochemistry. 1999 Aug 10;38(32):10388-97.

PMID:
10441133

Supplemental Content

Loading ...
Support Center